The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
AGILE: A phase 3, multicenter, randomized, placebo-controlled study of ivosidenib in combination with azacitidine in adult patients with previously untreated acute myeloid leukemia with an IDH1 mutation.
 
Eytan Stein
Consulting or Advisory Role - Agios; Bayer; Celgene; Novartis; Pfizer
 
Courtney Denton Dinardo
Honoraria - Agios; Daiichi Sankyo; Novartis
Research Funding - Abbvie; AGIOS; Celgene; Daiichi Sankyo; Novartis
 
Jun Ho Jang
No Relationships to Disclose
 
Yasushi Miyazaki
Honoraria - Celgene; Dainippon Sumitomo Pharma; Janssen; Kyowa Hakko Kirin; Nippon Shinyaku; Novartis
Consulting or Advisory Role - Agios; Dainippon Sumitomo Pharma; Shine Pharmaceuticals
Research Funding - Asterias Biotherapeutics; Chugai Pharma; Kyowa Hakko Kirin; Pfizer
 
Roberto Ovilla Martinez
No Relationships to Disclose
 
Julia Auer
Employment - Agios
Stock and Other Ownership Interests - Agios
 
Vickie Zhang
Employment - Agios
Stock and Other Ownership Interests - Agios
 
Daniel O. Koralek
Employment - Agios
Stock and Other Ownership Interests - Agios
 
Bin Wu
Employment - Agios
Stock and Other Ownership Interests - Agios
Patents, Royalties, Other Intellectual Property - Agios